Literature DB >> 1523301

Evaluation of radiation-induced liver injury with MR imaging: comparison of hepatocellular and reticuloendothelial contrast agents.

O Clément1, A Mühler, V S Vexler, W Rosenau, Y Berthezène, R Kuwatsuru, R C Brasch.   

Abstract

Gadolinium (4s)-4-(4-ethoxybenzyl-3,6,9-tris(carboxylato-methyl)-3,6,9- triazaudecandioic acid (EOB) diethylenetriaminepentaacetic acid (DTPA), a hepatocellular-directed magnetic resonance (MR) contrast agent, and coated superparamagnetic iron oxide particles (SPIO), a Kupffer cell-directed contrast agent, were compared for uptake and enhancement in a rodent model of radiation-induced liver injury. A single x-irradiation exposure (50-70 Gy) was delivered to one side of the liver in 18 rats. MR imaging was performed 3 days after x irradiation with sequential injections of the two contrast agents in the same rats. Additionally, biliary excretion of Gd-EOB-DTPA was quantified after whole-liver irradiation in five rats. Electron microscopy of the irradiated liver demonstrated mitochondrial injury in both hepatocyte and Kupffer cell populations. With Gd-EOB-DTPA, however, liver enhancement and biliary excretion were not affected by irradiation. Uptake of SPIO was decreased in the irradiated portion of the liver, with a precise demarcation between irradiated and nonirradiated zones at MR imaging.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1523301     DOI: 10.1148/radiology.185.1.1523301

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  8 in total

Review 1.  Focal liver lesions detection and characterization: The advantages of gadoxetic acid-enhanced liver MRI.

Authors:  Stefano Palmucci
Journal:  World J Hepatol       Date:  2014-07-27

Review 2.  Pathology and images of radiation-induced hepatitis: a review article.

Authors:  Shigeyuki Takamatsu; Kazuto Kozaka; Satoshi Kobayashi; Norihide Yoneda; Kotaro Yoshida; Dai Inoue; Azusa Kitao; Takahiro Ogi; Tetsuya Minami; Wataru Kouda; Tomoyasu Kumano; Nobukazu Fuwa; Osamu Matsui; Toshifumi Gabata
Journal:  Jpn J Radiol       Date:  2018-03-05       Impact factor: 2.374

3.  Correlation of liver parenchymal gadolinium-ethoxybenzyl diethylenetriaminepentaacetic acid enhancement and liver function in humans with hepatocellular carcinoma.

Authors:  Kei Kubota; Taiji Tamura; Nobutaka Aoyama; Munenobu Nogami; Norihiko Hamada; Akihito Nishioka; Yasuhiro Ogawa
Journal:  Oncol Lett       Date:  2012-03-01       Impact factor: 2.967

4.  Time-dependent changes in CT of radiation-induced liver injury: a preliminary study in gastric cancer patients.

Authors:  Yaqi Sheng; Qiuxia Wang; Zhen Li; Nannan Zheng; Yigang Pei; Liang Chen; Dayu Hu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-11-10

5.  Delayed hepatic signal recovery on ferucarbotran-enhanced magnetic resonance images in a rat model with regional liver irradiation.

Authors:  Toshihiro Furuta; Masayuki Yamaguchi; Ryutaro Nakagami; Masaaki Akahane; Manabu Minami; Kuni Ohtomo; Hirofumi Fujii
Journal:  MAGMA       Date:  2014-02-26       Impact factor: 2.310

6.  Delayed hepatic signal recovery on ferucarbotran-enhanced magnetic resonance images: an experimental study in rat livers with gadolinium chloride-induced Kupffer cell damage.

Authors:  Toshihiro Furuta; Masayuki Yamaguchi; Ryutaro Nakagami; Masaaki Akahane; Manabu Minami; Kuni Ohtomo; Noriyuki Moriyama; Hirofumi Fujii
Journal:  MAGMA       Date:  2012-11-02       Impact factor: 2.310

7.  Evaluation of acute esophageal radiation-induced damage using magnetic resonance imaging: a feasibility study in mice.

Authors:  Pouya Jelvehgaran; Jeffrey D Steinberg; Artem Khmelinskii; Gerben Borst; Ji-Ying Song; Niels de Wit; Daniel M de Bruin; Marcel van Herk
Journal:  Radiat Oncol       Date:  2019-10-30       Impact factor: 3.481

8.  Evolving development of multi-parametric normal tissue complication probability model for liver radiotherapy.

Authors:  Chiao-Ling Tsai; Jason Chia-Hsien Cheng
Journal:  Transl Cancer Res       Date:  2019-03       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.